AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$GRAL

What GRAIL (GRAL) Said on Its Q3 Earnings Call

GRAIL (GRAL) reported Q3 revenue of $37.3M, up 14%, with test volume increasing 24%. Adjusted gross margin fell to 42% from 55% YoY. The company maintained 2026 cash burn guidance of no more than $300M. GRAIL cited clinical study results showing increased cancer detection and reductions in advanced-stage diagnoses. They expect FDA approval to support reimbursement efforts.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 1:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What GRAIL (GRAL) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GRALBearishMed
01

Why it matters

The earnings release provides fresh data on growth, pricing, and cash runway, shaping short‑term trader sentiment.

02

Market read

GRAIL's Q3 earnings introduce new margin and pricing information that could move the stock in after‑hours trading.

03

What to watch

Potential FDA approval and upcoming European IVDR decision could offset short‑term margin pressure.

Relevance 8/10Novelty 8/10Timing: post‑market earnings release

Background

GRAIL reported Q3 results, highlighting a 14% revenue increase, a pricing promotion, and a suspended royalty to Illumina.

Company-level read

Ticker impact

$GRALBearishHigh confidence
Context

Q3 earnings disclosed revenue, margin decline, pricing promotion and cash guidance for the first time.

Expected impact

likely downside as market prices in lower margins and pricing promotion

Evidence & confidence

Adjusted gross margin fell to 42% from 55% YoY and adjusted EBITDA widened to a $92.6M loss, indicating pressure on profitability.

Market effects

Sector

Early‑stage cancer‑screening sector may see heightened scrutiny on pricing and margin dynamics.

Regional

U.S. biotech investors could adjust exposure ahead of upcoming regulatory decisions.

Global

Limited to GRAIL and peers; no broad market effect.

Counterpoint

What could challenge this read

Margin compression may be temporary as the pricing promotion drives volume growth and long‑term scale could improve profitability.

Key entities

  • company
    GRAIL

    NASDAQ‑listed early‑cancer detection firm.

  • company
    Illumina

    Royalty payer to GRAIL, pending resume of payments.

Read at source← All news

StoryGRAIL reports Q3 results and receives favorable FDA advisory committee vote for Galleri

Also covered by

4 outlets

Related articles

$GRALMed

Grail tumbles as revenue misses estimates despite FDA vote

Grail Inc (GRAL) reported Q3 revenue of $37.5M, missing estimates by 17%. The company posted a loss of $2.21 per share, with revenue up 4% YoY. Galleri test revenue grew 14% YoY to $37.3M. Stock fell 11.5% in after-hours trading. FDA Advisory Committee voted in favor of Galleri test approval. GRAL anticipates an FDA decision by early Q1 2027. Q3 net loss was $103.6M, up from $89.0M YoY.

investing.com
$GRALMed

GRAIL Reports Third Quarter 2026 Financial Results

GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE Exhibit 99.1 GRAIL Reports Third Quarter 2026 Financial Results FDA Advisory Committee Voted in Favor of Approval of GRAIL’s Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume

SEC EDGAR 8-K
$GRALMed

GRAIL Reports Third Quarter 2026 Financial Results

GRAIL (GRAL) reported Q3 2026 revenue of $37.5M, up 4% YoY, with Galleri test revenue growing 14% to $37.3M. Test volume increased 24% YoY to 56,000. Net loss was $103.6M. FDA advisory committee voted in favor of Galleri's approval, with a decision expected in Q1 2027. Galleri showed increased cancer detection in trials, reducing late-stage diagnoses.

prnewswire.com
$GRALMed

GRAIL, Inc. (GRAL) Surged After FDA Panel Backed Its Cancer Detection Test: Here’s Why

GRAIL, Inc. (GRAL) shares rose after an FDA panel backed its cancer detection test, potentially leading to FDA approval and insurance coverage. The company's stock has traded between $41.50 and $166.48 over the past year, closing at $133.76 on November 2, 2026. Mott Capital Management highlighted GRAL in its Q3 2026 investor letter, noting the test's potential and the role of AI in its development.

finance.yahoo.com